Hepatitis C in haemophiliacs

Area of Science:

• Hepatology
• Virology
• Hematology

Background:

• Hepatitis C virus (HCV) infection is prevalent in hemophiliacs due to non-virucidal clotting factor concentrates used before 1986.
• While some individuals clear HCV naturally, many develop chronic infection, with a significant subset co-infected with human immunodeficiency virus (HIV).
• HIV co-infection accelerates liver disease progression, including cirrhosis and liver failure, in HCV-infected hemophiliacs.

Purpose of the Study:

• To review the current understanding of HCV infection in hemophiliacs.
• To discuss the efficacy of existing and emerging treatments for chronic HCV in this population.
• To highlight considerations for managing HCV/HIV co-infection in hemophiliacs.

Main Methods:

• Review of existing literature on HCV infection in hemophiliacs.
• Analysis of treatment outcomes for interferon-based therapies.
• Evaluation of ongoing clinical trials for pegylated interferon.

Main Results:

• Interferon (IFN) monotherapy yielded poor results for chronic hepatitis C.
• Combination therapy with interferon and ribavirin has become the standard of care, improving outcomes.
• Pegylated interferon is under investigation and shows promise for HCV-chronically infected hemophiliacs.

Conclusions:

• HCV infection remains a significant concern for hemophiliacs, particularly those treated before 1986.
• Combination therapy with interferon and ribavirin is effective, and pegylated interferon offers a promising future treatment.
• Anti-HCV treatment should be considered for co-infected hemophiliacs once HIV is stabilized with anti-retroviral therapy.